Ipsen Pharma S.A.S.
Records under this name other than the patents Ipsen Pharma S.A.S. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 24 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,458,195 | Melanocortin Receptor Ligands Formerly held In force · High confidence | In force | High confidence | |
| US 9,102,921 | Protein delivery system to generate induced pluripotent stem (iPS) cells or tissue-specific cells Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,511,023 | Clay compositions Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,150,637 | Variant of Antihemophilic Factor VIII Having Increased Specific Activity Formerly held In force · High confidence | In force | High confidence | |
| US 10,053,500 | Variant of Antihemophilic Factor VIII Having Increased Specific Activity Formerly held In force · High confidence | In force | High confidence | |
| US 8,940,482 | N-end rule protease activity indication methods and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,753,633 | Compositions and Methods for Treatment of Pain Formerly held In force · High confidence | In force | High confidence | |
| US 11,969,484 | Composition Containing a Somatostatin Analogue for Radiopharmaceutical Use Formerly held In force · High confidence | In force | High confidence | |
| US 12,329,830 | Composition Containing a Somatostatin Analogue for Radiopharmaceutical Use Formerly held In force · High confidence | In force | High confidence | |
| US 9,850,280 | Melanocortin Receptor Ligands Term ended Term ended Jul 10, 2026 · Medium confidence | Term ended | Term ended Jul 10, 2026 | Medium confidence |